Ranbaxy Claims Greatest Indian Market Share, Ahead of Cipla, GSK
This article was originally published in PharmAsia News
Ranbaxy Laboratories beat out Cipla as India's drug maker with the highest share of the domestic market in July. Ranbaxy claimed a 5.1 percent market share during the month, while Cipla recorded a 4.89 percent share. Ranbaxy's sales for the month increased by 13.4 percent compared with Cipla's 9.7 percent. The audit by ORG-IMS gave U.K. drug maker GlaxoSmithKline the third largest market share, followed by Indian makers Piramal Healthcare and Zydus Cadila. (Click here for more
You may also be interested in...
MUMBAI - India's largest multinational drug maker GlaxoSmithKline is planning a big entry into the country's rural pharmaceutical market. An exhaustive plan is being hammered out to understand the dynamics of the rural medicine market so that GSK can position itself correctly in the intensely price-sensitive market segment
Garden of Life offers Triple Action Dr. Formulated; BasicBites Synergy Plus for oral care; Zicam extends to Daily Immune Support and Sleep + Immune Support with melatonin; Novastell launches Preminity for PMS; Prunelax in gummy; and lion’s mane mushroom in Clear Focus.
As legislation authorizing Medicare price 'negotiation' clears the Senate and appears on its way toward enactment after years of efforts by US congressional Democrats, and opposition by Republicans and the pharmaceutical industry, the bill continues to be tweaked.